Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemagen's test pinpoints long-term HIV survivors:

This article was originally published in Clinica

Executive Summary

Hemagen has completed the development of a new diagnostic test kit that can identify HIV patients who have an antibody that prevents them from developing full-blown AIDS. The assay could help doctors chose the best therapy for patients with the virus, sparing those who are unlikely to progress onto AIDS from unnecessary treatments. The test identifies an antibody, called anti-R7V, that appears to neutralise the HIV virus, says the Columbia, Maryland company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel